Baiteng Zhao is the founder of ProfoundBio. ProfoundBio has raised $250M in total funding. Latest round: Series B. Based in Seattle, United States.
Baiteng Zhao is the co-founder, CEO, and board chair of ProfoundBio, a clinical-stage biotechnology company focused on developing novel antibody-drug conjugate (ADC) therapeutics for cancer patients. ProfoundBio has raised over $250 million, including a recent $112 million Series B round, to support its pipeline of ADCs. Before co-founding ProfoundBio, Zhao was an associate director at Seagen, an ADC pioneer later acquired by Pfizer.
Full founder directory · Investor directory · Company funding database · Fundraising library